The University of Michigan has been participating as a fully funded member with Southwest Oncology Group (SWOG) since January 1, 1980. We view SWOG participation as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goals as a member institution in SWOG remain the same as in years past, namely to make significant scientific, administrative and patient data contributions to the Group's effort to study and improve cancer therapy. We continue to believe in the cooperative group process that involves the collection of patient data, adopting uniform toxicity and response criteria, and conducting purposeful clinical trials as well as introducing the concept of merging """"""""spores"""""""" into the cooperative group mechanism. Cooperative groups have provided the only settings in which the sophisticated concepts of combined modality and adjuvant therapies could be properly investigated. The processes have also produced an improved understanding of the important relationships between prognostic factors, therapy and patient survival that could not have been gained otherwise. Our participation in SWOG is multidisciplinary with membership that included hematologists, medical oncologists, radiation oncologists, pathologists, surgeons and various surgical subspecialties (in particular urology oncology, orthopedics, breast, otolaryngology, gynecology and thoracic), nurses and clinical research associates all involved in group activities which has strengthened with the recruitment of senior leadership, as well as talented junior faculty to complement an already strong base of clinical and basic researchers. Our participation in SWOG during the last five years has been characterized by a high level of data management and protocol compliance, good level of administrative/scientific contributions and an average level of patient registration contributions, (1997 =41 pts, 1998= 33 pts, 1999= 47 pts, 2000= 33 pts, 2001 = 57 pts, 2002= 17 pts; total= 225 pts). We expect to increase patient accrual to approximately 50-100 pts per year with the increased commitment amongst SWOG investigators at the University of Michigan and CGOP affiliates.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA027057-25
Application #
6731250
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1980-01-01
Project End
2006-12-31
Budget Start
2004-07-16
Budget End
2004-12-31
Support Year
25
Fiscal Year
2004
Total Cost
$178,101
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Prebet, Thomas; Sun, Zhuoxin; Ketterling, Rhett P et al. (2016) Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol 172:384-91
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Whelan, Timothy J; Olivotto, Ivo A; Parulekar, Wendy R et al. (2015) Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 373:307-16
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64

Showing the most recent 10 out of 194 publications